Ihsan Khan, MD
Pulmonary Disease · Binghamton, NYNPI 1578876991
Payments from drug & device makers
Across 610 payments — averaging $1707.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1M
- GSK$2K
- AstraZeneca$1K
- Boehringer Ingelheim$880
- Electromed, Inc.$829
- Sanofi$498
- plus $4K from 26 others
What the payments were for
- Food & beverage$8,78398%
- Education$2082%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 118 | $1,032,306 |
| GSK | 166 | $2,110 |
| AstraZeneca | 56 | $1,155 |
| Boehringer Ingelheim | 59 | $880 |
| Electromed, Inc. | 21 | $829 |
| Sanofi | 29 | $498 |
| Regeneron Healthcare Solutions, Inc. | 23 | $428 |
| Johnson & Johnson(2 entities) | 11 | $386 |
| Amgen | 18 | $345 |
| Mallinckrodt Hospital Products Inc. | 12 | $333 |
| Grifols USA, LLC | 16 | $280 |
| Insmed, Inc. | 13 | $217 |
| Verona Pharma, Inc. | 11 | $207 |
| Pulmonx Corporation | 5 | $205 |
| Actelion Pharmaceuticals US, Inc. | 6 | $158 |
| Genentech USA, Inc. | 7 | $134 |
| Merck | 1 | $113 |
| Novartis | 5 | $111 |
| Teva Pharmaceuticals USA, Inc. | 5 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $77 |
| Mylan Specialty L.p. | 5 | $72 |
| Shire North American Group Inc | 3 | $58 |
| Philips North America LLC | 2 | $45 |
| Sunovion Pharmaceuticals Inc. | 4 | $45 |
| Inspire Medical Systems, Inc. | 2 | $45 |
| Jazz Pharmaceuticals Inc. | 2 | $43 |
| Circassia Inc. | 2 | $41 |
| CSL Behring | 1 | $27 |
| Tactile Systems Technology Inc | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Itamar Medical Inc | 1 | $17 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SMARTVEST$470
- AIRSUPRA$239
- FASENRA$239
- CHARTIS CATHETER$120
- ZEPHYR DELIVERY CATHETER$120
- ZEPHYR ENDOBRONCHIAL VALVE$120
- PULMONX CHARTIS TABLET CONSOLE$120
- IMBRUVICA$113
- WINREVAIR$113
- SYMBICORT$108
- BREZTRI$108
- XARELTO$107
How this compares
$1,041,298 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 755 | $613,693 |
| Breo ElliptaFluticasone/Vilanterol | 492 | $252,549 |
| Dupixent PenDupilumab | 53 | $200,928 |
| Spiriva RespimatTiotropium Bromide | 160 | $120,734 |
| Incruse ElliptaUmeclidinium Bromide | 246 | $102,951 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 174 | $99,434 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 118 | $90,158 |
| Dupixent SyringeDupilumab | 16 | $59,007 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 77 | $48,788 |
| SymbicortBudesonide/Formoterol Fumarate | 164 | $46,940 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 328 | $46,545 |
| Spiriva HandihalerTiotropium Bromide | 47 | $32,417 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 927 | $31,654 |
| Arnuity ElliptaFluticasone Furoate | 99 | $24,578 |
| Advair HfaFluticasone Propion/Salmeterol | 57 | $21,401 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $2,110 | $1,093,2041,766 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $880 | $169,522237 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,155 | $152,265314 claims |
| MerckDulera | $113 | $4,16413 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $82 | $3,63513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Binghamton
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.